Surufatinib Combined With Toripalimab & AG Regiments for First-line

See also
Status	Clinical Trial	Phase
Completed	`NCT00753675` - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer	Phase 2
Completed	`NCT01844245` - Endobiliary RFA for Unresectable Malignant Biliary Strictures	N/A
Recruiting	`NCT02238613` - Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT00753675 - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

Phase 2

Completed

NCT01844245 - Endobiliary RFA for Unresectable Malignant Biliary Strictures

N/A

Recruiting

NCT02238613 - Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT06062485
Study type	Interventional
Source	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact	Du Juan, M.D. Ph.D
Phone	86-025-83106666
Email	dujunglyy@163.com
Status	Not yet recruiting
Phase	Phase 2
Start date	October 2023
Completion date	October 2026

Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms